Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.48 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028060 | 0.90 | MAPT (0.60) | MAPTALDH1A1ERCC1ERCC4P2RX7 | |
| SCHEMBL20027784 | 0.89 | MAPT (0.52) | MAPTALDH1A1CARM1ERCC1ERCC4 | |
| SCHEMBL20028050 | 0.88 | KMT2A (0.52) | MAPTALDH1A1CARM1ERCC1ERCC4 | |
| SCHEMBL20028492 | 0.87 | MAPT (0.54) | MAPTALDH1A1CARM1MDM2MAPK14 | |
| SCHEMBL20028522 | 0.86 | MAPT (0.59) | MAPTALDH1A1CARM1MDM2GAA | |
| SCHEMBL20027768 | 0.85 | MAPT (0.52) | MAPTALDH1A1CARM1MDM2MAPK14 | |
| SCHEMBL22897252 | 0.83 | MAPT (0.50) | MAPTALDH1A1CARM1MDM2GAA | |
| SCHEMBL18622976 | 0.81 | MAPT (0.48) | MAPTALDH1A1CARM1MDM2MAPK14 | |
| SCHEMBL20027808 | 0.81 | MAPT (0.47) | MAPTALDH1A1CARM1 | |
| SCHEMBL21854228 | 0.81 | MAPT (0.47) | MAPTALDH1A1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | MAPT 562/4885ALDH1A1 4193/4885CARM1 1986/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | MAPT 330/4885ALDH1A1 4421/4885CARM1 2763/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | MAPT 562/4885ALDH1A1 4193/4885CARM1 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.